NeoGenomics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M | $484.3M | $444.4M | $408.8M | $276.7M |
| Cost of Revenue | $413.0M | $370.5M | $347.0M | $321.8M | $297.3M | $258.6M | $212.0M | $149.5M |
| Gross Profit | $314.3M | $290.1M | $244.6M | $187.9M | $187.1M | $185.9M | $196.8M | $127.3M |
| Gross Margin | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | 46.0% |
| Operating Expenses | ||||||||
| Research & Development | $37.1M | $31.2M | $27.3M | $30.3M | $21.9M | $8.2M | $8.5M | $3.0M |
| SG&A Expense | $273.3M | $259.7M | $243.1M | $243.4M | $221.3M | $143.8M | $128.0M | $84.8M |
| Operating Income | $-115.9M | $-92.1M | $-107.7M | $-157.6M | $-118.8M | $-14.0M | $13.0M | $10.0M |
| Operating Margin | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | 3.6% |
| Interest Expense | — | — | $6.9M | $7.6M | $8.2M | $7.0M | $3.7M | $6.2M |
| Pretax Income | $-110.3M | $-80.7M | $-97.1M | $-159.3M | $-15.1M | $-14.1M | $3.6M | $3.8M |
| Income Tax Expense | $-2.2M | $-1.9M | $-9.1M | $-15.1M | $-6.7M | $-18.2M | $-4.4M | $1.2M |
| Net Income | $-108.0M | $-78.7M | $-88.0M | $-144.3M | $-8.3M | $4.2M | $8.0M | $2.6M |
| Net Margin | -14.9% | -11.9% | -14.9% | -28.3% | -1.7% | 0.9% | 2.0% | 1.0% |
| EPS (Basic) | $-0.84 | $-0.62 | $-0.70 | $-1.16 | $-0.07 | $0.04 | $0.08 | $0.07 |
| EPS (Diluted) | $-0.84 | $-0.62 | $-0.70 | $-1.16 | $-0.07 | $0.04 | $0.08 | $0.07 |
| Shares Outstanding (Basic) | 128.1M | 126.7M | 125.5M | 124.2M | 120.0M | 108.6M | 100.5M | 85.6M |
| Shares Outstanding (Diluted) | 128.1M | 126.7M | 125.5M | 124.2M | 120.0M | 111.8M | 103.6M | 91.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |